Department of Dermatology, Hospital Clínico San Carlos, Profesor Martín Lagos s/n, 28040, Madrid, Spain,
Am J Clin Dermatol. 2014 Feb;15 Suppl 1:S17-24. doi: 10.1007/s40257-013-0055-3.
Psoriasis is a systemic chronic inflammatory disease that affects 1-3% of the world's population. Knowledge of the pathogenesis of psoriasis, particularly in the understanding of the role of T cells and tumor necrosis factor α (TNFα), and advances in immunology have led to the development of biological agents, which, due to their great effectiveness, speed of response and good tolerability, have revolutionized patient management. One of these is infliximab, a human chimeric immunoglobulin G1 monoclonal antibody composed of human antibody constant regions and murine variable regions that was developed specifically to target TNFα. The six cases presented in this series highlight the feasibility, efficacy and safety of infliximab for psoriasis when administered in a variety of patients in several infusion centers across Spain. All six patients showed improvement in their psoriasis after the initiation of infliximab and no significant tolerability issues or injection site reactions were reported, despite the presence of several comorbid conditions or patient characteristics that traditionally reduce the efficacy of psoriasis treatments. This suggests that while the management of psoriasis patients with comorbid conditions and various unfavorable prognostic characteristics requires a multidisciplinary approach to ensure the patient obtains the best therapeutic response, infliximab is an effective and well tolerated treatment in these patients.
银屑病是一种全身性慢性炎症性疾病，影响全球 1-3%的人口。对银屑病发病机制的认识，特别是对 T 细胞和肿瘤坏死因子 α（TNFα）作用的认识，以及免疫学的进步，导致了生物制剂的发展，由于其有效性高、起效快、耐受性好，这些生物制剂彻底改变了患者的治疗管理。其中一种是英夫利昔单抗，这是一种人源化 IgG1 单克隆抗体，由人抗体恒定区和鼠可变区组成，专门针对 TNFα 开发。本系列中的 6 个病例突出了英夫利昔单抗在西班牙多个输注中心的多种患者中用于银屑病的可行性、疗效和安全性。在开始使用英夫利昔单抗后，所有 6 名患者的银屑病均有改善，且尽管存在多种合并症或传统上降低银屑病治疗效果的患者特征，但未报告明显的耐受性问题或注射部位反应。这表明，尽管需要多学科方法来管理患有合并症和各种不良预后特征的银屑病患者，以确保患者获得最佳的治疗反应，但英夫利昔单抗对这些患者是一种有效且耐受性良好的治疗方法。
